

Newcastle University ePrints

Vasen HFA, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Moller P, Myrhoj T, Nagengast FM, Parc Y, de Leon MP, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJW, Rahner N, Wijnen JT, Jarvinen HJ, Moslein G, the Mallorca Group. [Revised guidelines for the clinical management of Lynch syndrome \(HNPCC\): recommendations by a group of European experts.](#)

Gut 2013, 62(6), 812-823.

Copyright:

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: <http://creativecommons.org/licenses/by-nc/3.0/> and <http://creativecommons.org/licenses/by-nc/3.0/legalcode>

Link to published article:

<http://dx.doi.org/10.1136/gutjnl-2012-304356>

Date deposited: 2nd December 2014



This work is licensed under a [Creative Commons Attribution-NonCommercial 3.0 Unported License](http://creativecommons.org/licenses/by-nc/3.0/)

ePrints – Newcastle University ePrints

<http://eprint.ncl.ac.uk>



OPEN ACCESS

Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts

Hans F A Vasen,¹ Ignacio Blanco,² Katja Aktan-Collan,³ Jessica P Gopie,⁴ Angel Alonso,⁵ Stefan Aretz,⁶ Inge Bernstein,⁷ Lucio Bertario,⁸ John Burn,⁹ Gabriel Capella,² Chrystelle Colas,¹⁰ Christoph Engel,¹¹ Ian M Frayling,¹² Maurizio Genuardi,¹³ Karl Heinemann,¹⁴ Frederik J Hes,⁴ Shirley V Hodgson,¹⁵ John A Karagiannis,¹⁶ Fiona Lalloo,¹⁷ Annika Lindblom,¹⁸ Jukka-Pekka Mecklin,¹⁹ Pal Møller,²⁰ Torben Myrholm,⁷ Fokko M Nagengast,²¹ Yann Parc,²² Maurizio Ponz de Leon,²³ Laura Renkonen-Sinisalo,²⁴ Julian R Sampson,¹² Astrid Stormorken,²⁰ Rolf H Sijmons,²⁵ Sabine Tejpar,²⁶ Huw J W Thomas,²⁷ Nils Rahner,²⁸ Juul T Wijnen,⁴ Heikki Juhani Järvinen,²⁴ Gabriela Möslin,²⁹ (the Mallorca group)

For numbered affiliations see end of article

Correspondence to

Professor Dr Hans F A Vasen, Dutch Hereditary Cancer Registry & Department of Gastroenterology, Leiden University Medical Centre, Rijnsburgerweg 10, Leiden 2333 AA, The Netherlands; hfavasen@stoet.nl

Received 17 December 2012
Revised 15 January 2013
Accepted 16 January 2013
Published Online First
13 February 2013

ABSTRACT

Lynch syndrome (LS) is characterised by the development of colorectal cancer, endometrial cancer and various other cancers, and is caused by a mutation in one of the mismatch repair genes: *MLH1*, *MSH2*, *MSH6* or *PMS2*. In 2007, a group of European experts (the Mallorca group) published guidelines for the clinical management of LS. Since then substantial new information has become available necessitating an update of the guidelines. In 2011 and 2012 workshops were organised in Palma de Mallorca. A total of 35 specialists from 13 countries participated in the meetings. The first step was to formulate important clinical questions. Then a systematic literature search was performed using the Pubmed database and manual searches of relevant articles. During the workshops the outcome of the literature search was discussed in detail. The guidelines described in this paper may be helpful for the appropriate management of families with LS. Prospective controlled studies should be undertaken to improve further the care of these families.

INTRODUCTION

Lynch syndrome (LS) (previously referred to as hereditary non-polyposis colorectal cancer; HNPCC) is an autosomal dominant condition caused by a defect in one of the mismatch repair (MMR) genes.¹ The syndrome is characterised by the development of colorectal cancer (CRC), endometrial cancer (EC) and various other cancers frequently diagnosed at an early age. LS is probably the most common hereditary CRC syndrome accounting for approximately 1–3% of all CRC. It has been estimated that in Europe approximately one million individuals are carriers of an MMR defect.²

In 2007, a group of European experts (the Mallorca group) published guidelines for the clinical management of LS.³ Since then substantial new information has become available necessitating an update of the guidelines. We used the same approach as for the development of the previous

guidelines. In 2011 and 2012 workshops were organised in Palma de Mallorca. A total of 35 specialists from 13 countries participated in the meeting. The group consisted of surgeons, clinical geneticists, molecular geneticists, pathologists, oncologists, epidemiologists and gastroenterologists. If a particular speciality was not represented specialists outside the group were consulted.

The first step was to formulate important clinical questions. Then a systematic literature search was performed using the Pubmed database and manual searches of relevant articles. During the workshops the outcome of the literature search was discussed in detail. Table 1 shows the criteria that were used for evaluation of studies, for the categorisation of evidence that they represented and for the strength of the recommendations that were made.

SHORT UPDATE ON LS

LS was first described by Aldred Warthin in 1913.⁴ In 1966, Henry Lynch reported two large families with hereditary CRC from the midwest.⁵ Since then, many hundreds of families with the same pattern of cancer occurrence have been identified throughout the world. In the early 1990s the underlying gene defect was discovered, that is, a mutation in one of the MMR genes *MLH1*, *MSH2*, *MSH6* or *PMS2*. Recently, two groups reported that a constitutional 3' end deletion of *EPCAM*, which is immediately upstream of the *MSH2* gene, may cause LS through epigenetic silencing of *MSH2*.^{6,7}

An MMR gene defect leads through loss of the corresponding normal alleles in the tumours of carriers to loss of MMR function and results in an accumulation of mutations in (coding and non-coding) microsatellites in such tumours (so-called microsatellites instability; MSI). Carriers of an MMR gene mutation have a very high risk of developing CRC (25–70%) and EC (30–70%) and an increased risk of developing other tumours. The main clinical features are an early age of onset and the occurrence of multiple tumours.



Open Access
Scan to access more
free content

Table 1 Validity and grading of recommendations

Category of evidence		Grading of recommendations
Meta-analysis of randomised controlled trials	Ia	A
Randomised controlled trial	Ib	A
Well-designed controlled study without randomisation	IIa	B
Well-designed quasi-experimental study	IIb	B
Non-experimental descriptive study	III	B
Expert opinion	IV	C

Since 2007, many studies have been published on the risk of developing non-CRC, non-EC cancers in carriers of an *MLH1* gene mutation, *MSH2* gene mutation and *MSH6* gene mutation.^{8–21} Such studies are not yet available for carriers of a *PMS2* gene mutation. A summary of the findings is shown in table 2. Those new studies also reported increased risks for pancreatic, bladder and breast cancer and possibly prostate cancer. Notably, carriers of *MSH6* mutations appear to be particularly at risk of gastrointestinal cancer and EC, whereas carriers of an *MSH2* gene mutation have the highest cancer risks across the spectrum, especially for the development of urinary tract cancer. The risks for *MLH1* gene mutation carriers are between the cancer risks reported for *MSH6* carriers and those for *MSH2* carriers.^{8–21}

Moreover, a recent study reported on increased cancer risks for individuals with an *EPCAM* deletion.²² The investigators compared the cancer risks between 194 carriers of an *EPCAM* deletion and 473 carriers of a mutation in *MLH1*, *MSH2*, *MSH6* or a combined *EPCAM-MSH2* deletion. The risk of developing CRC for *EPCAM* deletion carriers was similar (75% by age 70 years) to the risks in carriers of an *MLH1* or *MSH2* mutation or a combined *EPCAM-MSH2* deletion but was higher than the risk in *MSH6* mutation carriers. By contrast, the risk of EC (12% by age 70 years) was significantly lower in female carriers of an *EPCAM* deletion compared to the risk in carriers of an *MSH2* or *MSH6* mutation or a combined *EPCAM-MSH2* deletion. The EC risk in *EPCAM* deletion carriers was also lower than the risk in *MLH1* carriers but this difference was not statistically significant.

The wide variation in cancer risk within and between families is direct evidence that the risk is influenced by environmental and genetic factors. In the past 5 years many genome-wide association studies in CRC patients have identified a total of 20 variants that are associated with an increased risk of sporadic CRC.²³ A Dutch study evaluated whether six of these variants act as modifiers of the CRC risk in 675 gene mutation carriers.²⁴ Two variants (rs16892766 and rs3802842) were reported to increase the CRC risk in LS, the latter only in female carriers. An Australian group evaluated the effect of nine variants on the CRC risk in 684 MMR gene mutation carriers.²⁵ They confirmed the association of the previously reported variants with CRC risk but only for *MLH1* carriers. A French group did not find an association between these and other variants in 748 mutation carriers.²⁶ In summary, more studies are needed to define the role of these variants in clinical practice.

QUESTION NO 1

How can we improve the identification of LS?

Relevant literature

Identification of individuals with LS is extremely important because they can benefit from life-saving intensive-cancer surveillance.²⁷ However, it is the experience of most physicians specialising in familial cancer that LS is underdiagnosed.²⁸

Table 2 Cumulative risk (%) of non-colonic and non-endometrial cancers according to type of mismatch repair gene mutation by age 70 years

Tumour site	Mutation carriers			MLH1			MSH2			MSH6		
	All	M	F	All	M	F	All	M	F	All	M	F
Gastric ^{8,9,11–13,17,19}	0.7/9.4/0.7	6.2/6.7	2.0/2.6	2.1/3.5/6.1/10.9			0.2/4.3/5.2/6.7/7.8			0.0/0/10.4		
Small bowel ^{9,11–13,15,19}	0.6/2.5/4.2	4.1/6.1/12	2.7/3.9/4.1	0.4/4.4/4.5/7.2/8			1.1/1.3/4.5/5.9/8			0.0/0/3		
Biliary tract ^{8,11,13}	0.6/1.4/2			1.9/3			0.02/0.4			0/0		
Pancreas ^{11,20}	0.4/3.7			0			0.7			0		
Urinary tract ^{8,9,11–13,18}	1.9/3.2/4/8.4			0.2/1.3/2.8	3.7/15.6	1.1/2.4	2.2/4.1/12	27.8/18.2	11.9/8.4	0.0/7	2.6	0
Upper urinary tract ^{2,18,19}	6.0	9.1/9.4	5.4/6.0	1	2.1/4.8	2.4/0.4	15	5.9/20.3	5.8/9.1	1.5	1.3	0
Bladder ^{18,19}		5.5/16.4	1.9/3.5	1	10.8	0	8	12.3	2.6	1	1.3	0
Ovaries ^{8–13,19}			6.1/8/12/13.5			3.4/3.9/5.5/6.3/20			7.5/8.3/10/10.4/11.6/24			0/1.0/10
Brain ^{8,9,11,12}	3.4/3.7			0/0.3/1.7			1.2/2.5/6.3			0		
Prostate ^{11,12,19}		9.1/30			0			6/18			0/4	
Breast ^{12,16,19}			5.4/14.4			18/17			1.5/12			13

Guidelines

There are many ways to improve the identification of this syndrome that have been described in a previous report from our group.² For example, efforts should be aimed at increasing the awareness of hereditary CRC in the general population and at promoting the taking of an adequate family history in all patients visiting a physician. However, probably the most effective way to identify LS is via patients who are diagnosed with CRC or EC. Many criteria have been proposed to identify LS among these patients mainly based on age at CRC diagnosis, the presence of multiple tumours and the number of affected family members. The revised Bethesda guidelines are thus probably the most commonly used criteria to select patients with CRC for further molecular analysis of their tumours (MSI/immunohistochemistry).²⁹ However, these criteria and guidelines have been criticised for being too complex and lacking in specificity and sensitivity. As a consequence, the criteria are poorly implemented in clinical practice.

In view of these problems, systematic testing of all patients with CRC (or all individuals with CRC <70 years) has been recommended for loss of MMR function by means of MSI or immunohistochemistry independent of clinical criteria.³⁰

Since the 2007 guidelines, several studies have been published on the outcome of testing of all patients with CRC (or individuals with CRC <70 years) (table 3).^{31–36} The studies showed that this approach led to the identification of substantial numbers of LS mutation carriers (2.4–3.7% of all tested patients). Moreover, it was shown that many cases (12–28%) would have been missed if the revised Bethesda criteria had been used for selection. Two studies have shown that such an approach is cost effective.^{37 38}

An alternative approach to the identification of LS is by testing unselected cases of EC for MSI and/or immunohistochemistry. Two studies revealed that such an approach led to the identification of LS in a proportion of patients (1.8–3.9%) comparable with CRC testing^{39 40} (table 3). Molecular screening of EC has also been found to be cost effective.⁴¹

A recent study of molecular screening of sebaceous adenomas and carcinomas led to the detection of LS in a substantial proportion of cases (14%).⁴²

Due to the cascade effect, the identification of index cases by molecular screening leads on average to the detection of three additional relatives with LS, which demonstrates the utility of this approach and indicates its cost effectiveness.

Conclusion and recommendation

Testing all CRC (or individuals with CRC <70 years) and all EC (or individuals with EC <70 years) by immunohistochemistry or MSI is useful for the identification of patients with LS (category of evidence IIb). The Mallorca group recommends investigation of all CRC (or individuals with CRC <70 years) by immunohistochemistry of the four MMR proteins or MSI (grade of recommendation C). These tests should be accompanied by methods that identify MLH1 promotor methylation. Investigation of all EC in individuals less than 70 years by immunohistochemistry or MSI can be considered to improve identification (grade of recommendation C).

QUESTION NO 2

What is the optimal colorectal surveillance protocol for LS?

Table 3 Outcome of prospective molecular screening of CRC or LS-associated cancer

Author, year (reference)	No/type of cancer	Screening test	Outcome	Pathogenic mutation (%)	No of (%) mutation carriers fulfilling revised Bethesda guidelines	Type of mutations
Hampel <i>et al</i> (2008) ³¹	500 CRC	MSI, immunohistochemistry MLH1-methyl.	64 MSI-H (12.8%)	18 (3.6%)	13/18 (72%)	4 MLH1 10 MSH2 3 MSH6 1 PMS2
Julie <i>et al</i> (2008) ³²	214 CRC	MSI, immunohistochemistry, BRAF, MLH1-methyl.	21 MSI-H (9.8%)	8 (3.7%)	6/8 (75%)	2 MLH1 5 MSH2 1 MSH6
van Lier <i>et al</i> (2012) ³³	1117 CRC ≤70 years	MSI, immunohistochemistry MLH1-methyl.	121 MSI-H (10.9%)	50 LS-like* (4.5%); 42 tested: 27 (2.4%) mutations	20/27 (74%)	5 MLH1 5 MSH2 11 MSH6 5 PMS2 1 EPCAM
	125 Advanced adenoma ≤45 years	Idem		3 (2.4%) LS-like; 3 (2.4%) mutations	N.A.	2 MLH1 1 MSH2
Moreira <i>et al</i> (2012) ³⁶	10.206 CRC	MSI, immunohistochemistry MLH1-methyl.	1386 MSI-H (13.8%)	312 (3.1%)	78/82 (88%)	34 MLH1 33 MSH2 9 MSH6 6 PMS2
Canard <i>et al</i> (2012) ³⁵	1040 CRC	MSI, immunohistochemistry (partly) MLH1-methyl.	98 MSI-H (9.4%)	25 (2.4%)	22/25 (88%)	4 MLH1 19 MSH2 2 MSH6
Hampel <i>et al</i> (2006) ³⁹	543 EC	MSI, immunohistochemistry (partly) MLH1-methyl.	118 MSI-H (21.7%)	9 (1.8%)	N.A.	1 MLH1 2 MSH2 6 MSH6 2 PMS2
Leenen <i>et al</i> (2012) ⁴⁰	179 EC ≤70 years	MSI, immunohistochemistry MLH1-methyl.	42 MSI-H (23%)	11 (6.2%) LS-like; 7 mutations (3.9%)	N.A.	1 MLH1 2 MSH2 6 MSH6 2 PMS2
Plocharczyk <i>et al</i> (2012) ⁴²	36 Sebaceous tumours	Immunohistochemistry	14 MMR-protein loss (38.8%)	5 (14%)	N.A.	Not reported

*LS-like: loss of expression of MMR proteins compatible with presence of MMR gene mutation.

CRC, colorectal cancer; IHC, immunohistochemistry; LS, Lynch syndrome; MMR, mismatch repair; MSI, microsatellites instability; NA, not applicable.

Table 4 Outcome of colonoscopic surveillance in LS

Author/year	No of participants	Mean follow-up (years)	Interval recommend (years)	Risk interval cancer*		No of interval cancers	Location right colon (%)	Local stage (stage I & II) (%)	Death CRC
				By follow-up time	By age 60 years				
Mecklin <i>et al</i> (2007) ⁴⁴	420	6.7	2	–	M 35% F 22%	26	57	80	5
Engel <i>et al</i> (2010) ⁴⁶	1126	3.7	1	–	–	25	Not reported	95	Not reported
Vasen <i>et al</i> (2010) ⁴⁵	745	7.2	1–2	6%/10 years	–	33	62	83	0
Stuckless <i>et al</i> (2011) ⁴⁷	109	Ca 10	1–2	–	–	21	62	78	1

*Defined as CRC that develops after a negative screening colonoscopy. CRC, colorectal cancer; LS, Lynch syndrome.

Relevant literature

Colorectal surveillance is the only surveillance protocol in LS proved to be effective.⁴³ Regular colonoscopy leads to a reduction of CRC-related mortality and also to a significant reduction of overall mortality in contrast with CRC screening in the general population.²⁷

However, there is an ongoing discussion about the optimal interval between colonoscopic examinations. Although a 3-year interval between colonoscopies has been proved to be effective,⁴³ there are no studies that have compared the effectiveness between different intervals. Since 2007, three prospective studies and one retrospective study analysing the effectiveness of colonoscopic surveillance have been published.^{44–47} The characteristics of the study populations, the intervals that were recommended and the outcomes are summarised in table 4.

Unfortunately, it is difficult to compare the risks of developing an interval cancer (defined as a cancer that develops after a negative screening examination) between the studies due to the different methodologies used. The proportion of interval cancers with a local tumour (stages I and II) varied from 78% to 95%. Most tumours (57–62%) were located in the right colon, which emphasises the importance of careful investigation of this part of the colon. In the Dutch, German and Canadian series, most interval cancers were diagnosed in individuals older than 40 years. However, in the Finnish series a substantial proportion (20–30%) were diagnosed between the age of 30 and 40 years. In one study, the influence of the type of MMR gene defect on the risk of developing interval cancers was evaluated. That study demonstrated that the risk was lower for carriers of an *MSH6* gene mutation, although the difference was not statistically significant.

In the Finnish series, it was found that mortality due to CRC was associated with a lack of participation in the surveillance programme. This is concerning given that the lack of compliance with the recommended surveillance interval in the German and Canadian studies was 20% and 42%. To guarantee the continuity of surveillance and improve compliance with the surveillance recommendations patients should be registered at a regional or national hereditary cancer registry. Such registries can improve participation in surveillance by using reminder systems.⁴⁸

Conclusion

A 3-year interval between colonoscopies has been proved to be effective (category of evidence IIb). In view of the observation of (advanced) CRC detected between 2 and 3 years after surveillance colonoscopy, the recommended interval for mutation carriers is 1–2 years (grade of recommendation C).

QUESTION NO 3

How effective is surveillance for endometrial and ovarian cancer?

Relevant literature

In LS, the risk of developing EC is very high and equals or even exceeds the risk of CRC in female gene carriers.⁴⁹ The overall prognosis of patients diagnosed with EC is relatively good, with a 10-year survival of approximately 80%. However, 20% of the patients will ultimately die from the disease. Moreover, a substantial proportion of patients need treatment with radiation and/or chemotherapy.

The main goal of surveillance for EC is detection and treatment of premalignant lesions (ie, endometrial hyperplasia) or EC at an early stage and thereby improving the prognosis for the patients. The World Health Organization classifies endometrial hyperplasia as simple or complex determined by the degree of architectural abnormality, and as having or not having atypia. Nieminen *et al*⁵⁰ studied serial specimens of normal endometrium, simple hyperplasia and complex hyperplasia with and without atypia during 10 years of surveillance. MMR deficiency was observed in 7% of normal endometrium, 40% of simple hyperplasia, 100% of complex hyperplasia without atypia and 92% of complex hyperplasia with atypia, suggesting that in LS, contrary to the traditional view, complex hyperplasia with and without atypia was equally important as precursor lesions of EC.

In 2011, Auranen and Joutsiniemi⁵¹ performed a systematic review of all studies that addressed gynaecological cancer surveillance in women who belonged to LS families. The authors identified five studies in the literature that included a total of 647 women.^{52–56} The screening methods applied in the studies varied from only transvaginal (or transabdominal) ultrasound (two studies) to a combination of transvaginal ultrasound and endometrial biopsy (two studies) and hysteroscopic endometrial biopsy (one study). The intervals between examinations varied between 1 year in three studies, 1–2 years in one study and 2–3 years in another study. In the studies that used only ultrasound as the screening tool, no EC were detected and only interval cancers occurred. However, in the studies with a protocol that also included endometrial biopsies, the detection of premalignant lesions and EC was improved.

Renkonen-Sinisalo *et al*⁵⁴ compared the Federation of Gynecology and Obstetrics (FIGO) stages of the screen-detected cancers with those of EC diagnosed after presentation of signs or symptoms. Although less advanced cancers were observed in the screen-detected group, the difference was not statistically significant. The main advantage of the surveillance programme seems to be the identification of precursor lesions. No benefit was shown for ovarian cancer surveillance. Auranen and Joutsiniemi⁵¹ concluded that the available studies do not adequately allow for evidence-based clinical decisions.

Since that review, another retrospective study was published on the impact of gynaecological screening in *MSH2* carriers (n=54).⁵⁷ Nine women were diagnosed with EC, five of which were within 1 year of the previous negative screening test

Guidelines

(transvaginal ultrasound and/or endometrial biopsy) and two were at initial screening. Of the nine EC, seven were localised cancers (stage I), and one was at an advanced stage (stage III). There were no deaths due to EC. Six women had ovarian cancer, three of which were within 1 year of a previous normal screening. Two died from ovarian cancer. The authors concluded that gynaecological screening did not result in earlier detection of gynaecological cancer.

In view of the uncertain effect of the surveillance programme, it is important to consider possible disadvantages of the programme. Elmasry *et al*⁵⁸ assessed the patient acceptability of the available screening modalities. Transvaginal ultrasound was associated with less discomfort than hysteroscopy or Pipelle biopsy. There was no significant difference between the pain scores for hysteroscopy and Pipelle biopsy. Huang *et al*⁵⁹ compared a new patient-centered approach by combining endometrial biopsies and colonoscopy under sedation. This approach was much more acceptable than an endometrial biopsy as a single procedure without sedation.

Wood *et al*⁶⁰ evaluated the effect of gynaecological screening in LS families on psychological morbidity. The authors did not demonstrate any adverse psychological effect in the screened population, even in those with false positive screening results.

Conclusion

The value of surveillance for EC is still unknown. Surveillance of the endometrium by gynaecological examination, transvaginal ultrasound and aspiration biopsy starting from the age of 35–40 years may lead to the detection of premalignant disease and early cancers (category of evidence III) and should be offered to mutation carriers (grade of recommendation C). The pros and cons should be discussed (table 5). Given the lack of evidence of any benefit, gynaecological surveillance should preferably be performed as part of a clinical trial.

QUESTION NO 4

What is the role of prophylactic hysterectomy with or without oophorectomy?

Relevant literature

Schmeler *et al*⁶¹ have shown in a retrospective study that prophylactic hysterectomy and oophorectomy is very effective in LS: none of the patients who underwent prophylactic surgery (61 out of 315) developed endometrial or ovarian cancer, whereas 33% of patients who did not have surgery developed EC and 5.5% developed ovarian cancer.

A recent study documented two cases of LS patients who developed primary peritoneal cancers after prophylactic surgery.⁶² A cost-effectiveness analysis of prophylactic surgery versus gynaecological screening showed that risk-reducing surgery was associated with both the lowest costs and highest number of quality-adjusted life years.^{63 64}

In view of the very high risk of EC, the substantial proportion of women who will die from the disease, the morbidity

associated with treatment and the effectiveness of prophylactic surgery, there is agreement that the option of prophylactic hysterectomy should be discussed with mutation carriers who have completed their family. However, there are still some important questions that should be addressed.

First, should prophylactic surgery include salpingo-oophorectomy? The risk of developing ovarian cancer in mutation carriers is approximately 9% with the highest risks in *MLH1* and *MSH2* mutation carriers and the lowest risk in *MSH6* mutation carriers. Although the prognosis of unselected patients with ovarian cancer (and also of patients with ovarian cancer associated with *BRCA1* and *BRCA2* mutations) is very poor, recent studies suggested that the biology of ovarian cancer associated with LS may be different. Three studies showed that the majority of symptomatic ovarian cancers (77–81%) in LS are diagnosed at an early stage (FIGO stages I and II).^{65–67} In a multicentre study, Grindedal *et al*⁶⁶ collected a large number (n=144) of prospectively diagnosed cases of ovarian cancer and demonstrated a very good prognosis with a 10-year survival of 81%.

Prophylactic surgery in postmenopausal women should include salpingo-oophorectomy. However, salpingo-oophorectomy in premenopausal women is associated with various adverse effects such as an immediate onset of menopause as a result of oestrogen deprivation potentially resulting in vasomotor symptoms and possible sexual dysfunction. Oestrogen deprivation may also lead to a higher risk of osteoporosis. A large study by Madalinska *et al*⁶⁸ in 846 carriers of a *BRCA1* and *BRCA2* mutations reported significantly more endocrine symptoms in the patients who underwent prophylactic oophorectomy compared to women who underwent surveillance of the ovaries. No significant differences were observed in the level of sexual activities between the two groups, but women in the prophylactic surgery group reported significantly more discomfort (vaginal dryness and dyspareunia), less pleasure and less satisfaction during sexual activities. Despite this, the study did not reveal any other differences in quality of life. Usually, hormone replacement therapy is prescribed in premenopausal women after salpingo-oophorectomy, which may partly reduce the vasomotor symptoms but has no effect on sexual discomfort.⁶⁹

In view of the recent study that suggests a relatively good prognosis of ovarian cancer in LS, it is questionable whether the possible small gain in life expectancy outweighs the adverse effects of prophylactic salpingo-oophorectomy at a young age.

The second question is how these issues should be discussed with the patient and how the patient can be supported in their decision-making? The best approach is to inform the patient

Table 6 Pros and cons of prophylactic hysterectomy with and without salpingo-oophorectomy

Pros	Cons
Prevention of endometrial and ovarian cancer	Small risk of death
Prevention of morbidity related to treatment	Mortality surgery (0.1%)
	Morbidity surgery (5–9%)
	Pelvic surgery makes colonoscopy more difficult and painful and may reduce chance of full colonoscopy
	Psychosocial problems (10–20%)
	Early menopause depending of age at surgery
	Sexual problems related to hysterectomy and early menopause
	Probably very small risk of developing primary peritoneal carcinoma after oophorectomy
	Unnecessary removal

Table 5 Pros and cons of surveillance for gynaecological cancer

Pros	Cons
Identification of precursor lesions of endometrial cancer	Small risk of death
Identification of early stage endometrial cancer (not proved)	Physical burden of surveillance examination especially Pipelle biopsy
	No evidence of efficacy for early stage ovarian cancer detection
	Psychological burden

fully about all pros and cons of prophylactic surgery. As a basis for this discussion, the pros and cons are summarised in table 6. Depending on the type of information, a gynaecologist, geneticist, clinical psychologist or other specialists should be involved. Ideally, this information should also be available in written form.

The third question is from which age surgery should be recommended. The risk of endometrial and ovarian cancer increases from the age of 40 years. The optimal timing of prophylactic surgery, therefore, would be around the age of 40 years.

Conclusion

Hysterectomy and bilateral oophorectomy largely prevents the development of endometrial and ovarian cancer (category of evidence III) and is an option to be discussed with mutation carriers who have completed their families especially after the age of 40 years (grade of recommendation C). Also, if CRC surgery is scheduled, the option of prophylactic surgery at the same time should be considered. All pros and cons of prophylactic surgery should be discussed.

QUESTION NO 5

What is the effectiveness of surveillance for other cancers?

Gastric cancer

In LS, the cumulative risk of developing gastric cancer by the age of 70 years is approximately 5%. Recent studies have shown that there is no evidence for the clustering of gastric cancer in specific LS families.^{17 70}

In parts of the world with a high background incidence of gastric cancer in the population (Korea, Japan), the risk of developing gastric cancer in LS families is also higher, suggesting the role of environmental factors. Although not proved, the impression exists that the incidence of gastric cancer in LS in the western world seems to be decreasing in parallel to the declining incidence of gastric cancer in the general population.¹⁷

The prognosis in unselected patients with cases of gastric cancer is poor, with an average 5-year survival rate of 20–25%. According to the Lauren's classification, tumours are separated into 'diffuse', 'intestinal' and 'mixed' types.⁷¹ In 'high incidence' areas, patients with *Helicobacter pylori*-associated chronic gastritis may develop atrophy followed by intestinal metaplasia over time. This may culminate in neoplastic changes, especially adenocarcinoma of 'intestinal' type. Two studies showed that the majority of gastric cancer associated with LS is of the intestinal type (73–79%).^{17 72} The goal of surveillance for gastric cancer would be the detection of precursor lesions and gastric cancer at an early curable stage. It is well known that early detection of diffuse gastric cancer is extremely difficult, and for this reason prophylactic gastrectomy is recommended in carriers of a *CDH1* mutation. However, as most cancers in LS are of the intestinal type, regular upper gastrointestinal endoscopy may lead to the early detection of precursor lesions and early cancer. Indeed, a Finnish study reported potential precursor lesions in a substantial proportion of 73 MMR gene mutation carriers: *H pylori* infection was observed in 26%, atrophy in 14% and intestinal metaplasia also in 14%.⁷³ There are no (other) studies in the literature that have evaluated the effectiveness of surveillance for gastric cancer. In view of the relatively low risk of gastric cancer and the lack of established benefit, the Mallorca group does not advise surveillance for gastric cancer. On the other hand, the Mallorca group recommends screening mutation carriers for the presence of an *H pylori* infection and subsequent eradication if detected. In

countries with a high incidence of gastric cancer in LS, surveillance might be performed in a research setting.

Cancer of the small bowel

The risk of developing this cancer in carriers of an *MLH1* or *MSH2* mutation is approximately 5%. In carriers of a *MSH6* mutation, small bowel cancer is relatively rare. There is no evidence for the clustering of small bowel cancer in specific families.¹² The tumours in LS families are mainly located in the proximal small bowel (43%) and the jejunum (33%); 7% are located in the ileum.¹⁵ Patients with small bowel cancer have a poor prognosis. The 5-year survival rate is 30–35%.

A French study recently compared the use of CT enteroclysis and video-capsule endoscopy in 35 mutation carriers.⁷⁴ Video-capsule endoscopy detected three (10%) lesions of which two were missed by CT enteroclysis. The lesions included two adenomas and one jejunal cancer. Although the yield of this small study is noteworthy, more studies are needed to confirm the findings and to assess the cost effectiveness. Currently, the Mallorca group does not recommend surveillance for this cancer. As small bowel cancer is frequently located in the duodenum and ileum, we suggest inspection of the distal duodenum during upper gastrointestinal endoscopy (if performed) and also of the ileum during colonoscopy.

Cancer of the urinary tract

Many studies have reported an increased risk of urothelial cancers of the upper urinary tract in LS. Recent studies have also demonstrated an increased risk of bladder cancer.^{18 19 75} The estimated risk varies from 5% to 20%, with the highest risk in male carriers and those with an *MSH2* mutation. The risk for non-urothelial tumours was not increased.

The classic presenting sign of urothelial tumours is haematuria without pain. The prognosis of patients with urothelial tumours depends on the stage and grade of the tumours. The 5-year survival of non-invasive, low grade cancers is over 90%, while for those with high grade cancers, it is 60–70%. Periodic examination may lead to the detection of cancers at earlier stages.

Options for urinary tract cancer screening include dipstick testing of the urine for microscopic haematuria, urine cytology, screening for tumour-specific molecular markers in the urine and abdominal ultrasound. Cystoscopy is the gold standard for bladder cancer detection. However, although flexible cystoscopy has a high sensitivity and positive predictive value, it is not considered appropriate for screening in the general population or high-risk groups due to its cost, procedural nature, and (small) risks.

Urothelial carcinoma in the sporadic setting is known to be associated with tobacco, aryl amines and other chemical carcinogens. Urine cytology and cystoscopy have been used to screen workers who are at extremely high risk of developing bladder cancer through occupational exposure to known urothelial carcinogens. Although several non-randomised studies have documented a high incidence of bladder cancer in populations with heavy exposure to such carcinogens, they have not demonstrated that active screening alters the natural history of the disease in those who do develop bladder cancer.^{76–79}

One Danish study has evaluated the effectiveness of surveillance of the urinary tract in LS.⁸⁰ The study reviewed records of 3411 relatives from LS families (n=263), or families that met the Amsterdam criteria I or II (n=426) or that had been suspected of LS (n=288).

The authors collected results of urine cytology from the National Danish Pathology Database. A total of 977 patients had 1868 screening procedures involving a total of 3213 person

Guidelines

years (median 2.8 years, range 0–11.5). In two patients (0.1%), the screening led to the identification of asymptomatic urinary tumours (two small non-invasive bladder cancers). During the study 14 patients (of the 997) developed a urinary cancer, including five interval cancers. The tumours consisted of seven bladder cancers without invasion, four bladder cancers with invasion, one renal pelvis tumour with invasion and one renal pelvis tumour without invasion and one renal cell carcinoma. The sensitivity of urine cytology was 29% in diagnosing asymptomatic tumours. The corresponding specificity was 96%. Eleven out of the 14 tumours were diagnosed in *MSH2* families.

The authors concluded that urine cytology is not an appropriate screening method of screening for urinary tract cancer in LS. The study does not allow any conclusion to be made about the benefit of surveillance in subgroups of families (eg, those with the *MSH2* mutation). Although abdominal ultrasound has been recommended as a surveillance tool in LS, there are no reports on its effectiveness.

In view of the lack of evidence for the benefit of surveillance for urinary tract cancer, the Mallorca group does not recommend surveillance for urinary tract cancer in LS outside the setting of a research project.

Prostate cancer

Prostate cancer is the most common cancer in men. The prognosis of these tumours is relatively good, with a 10-year survival of all men with prostate cancer of 72%. Previous studies did not show a (significantly) increased risk of prostate cancer in men with LS^{11 75} However, three recent studies did reveal an increased risk of developing this cancer in LS. A study by Engel *et al*¹⁹ reported a significantly increased risk of prostate cancer in LS (17 cases in 1011 male mutation carriers; standardised incidence ratio (SIR) 2.5 (1.4–4)). The highest risk was found in carriers of a *MSH2* mutation (cumulative risk by the age of 70 years: *MSH2*: 18%; *MLH1*: 0%; *MSH6*: 4%). Another study reported a tenfold increased risk of prostate cancer in carriers of a *MSH2* mutation (four cases in 130 male mutation carriers) but the cumulative risk by the age of 70 years was only 6%.²¹ In the third study from Norway, out of 106 male carriers or obligate carriers of MMR mutations, nine had developed prostate cancer¹⁶ (six in *MSH2* carriers). Immunohistochemical analysis showed the absence of the corresponding MMR gene product in seven of eight available tumours. The number of men with a Gleason score between eight and 10 was significantly higher than expected. Kaplan–Meier analysis suggested that cumulative risk by 70 years in MMR mutation carriers may be 30% (SE 0.088) compared to 8.0% in the general population.

Prostate-specific antigen screening of the general population is generally not recommended due to the serious side-effects of treatment and the indolent course of most screen-detected cancers.

If the increased risk of prostate cancer and the development of aggressive tumours are confirmed in further studies of LS families, male gene carriers, especially of an *MSH2* mutation might benefit from surveillance.

Until more studies are available, the Mallorca group does not recommend surveillance for prostate cancer in LS families outside of appropriate research studies (see <http://impact-study.co.uk>).

Pancreatic cancer

Recent studies have revealed an increased risk of developing pancreatic cancer in LS. Kastinos *et al*²⁰ reported a RR of 8 across 147 families with an MMR gene mutation, and calculated a cumulative risk of 3.7% by the age of 70 years. Win

*et al*⁷⁵ studied 446 MMR mutation carriers and reported a SIR of 11 for pancreatic cancer. The prognosis of patients with pancreatic cancer is very poor, with an average life expectancy of 6 months after diagnosis.

However, the benefit of surveillance for pancreatic cancer in high-risk groups is unknown and as the reported absolute risk is relatively low, the Mallorca group does not recommend surveillance for this cancer in LS families outside the setting of a research programme.

Breast cancer

Whether breast cancer is part of the tumour spectrum of LS is controversial.^{8 81 82} Loss of MMR function has been reported in a substantial proportion of breast cancers in LS.^{83 84} In a large study by Watson *et al*,¹² the risk of breast cancer was not increased (5.4% by age 70 years). In contrast, two recent studies reported increased risks of developing breast cancer. Barrow *et al*¹¹ reported an increased risk only in *MLH1* carriers (18%). A large cohort study from the German and Dutch LS registry reported a significantly increased risk for developing breast cancer.¹⁹ The cumulative risk by the age of 70 years was 14% in all female carriers, with the highest risk in *MLH1* carriers (*MLH1*: 17%; *MSH2*: 14.4%; *MSH6*: 11%). The risk of developing breast cancer started to increase after the age of 40 years. Win *et al*⁷⁵ reported a SIR of 3.95 for breast cancer in the follow-up of a cohort of 446 unaffected carriers of a MMR gene mutation.

Further studies are needed to confirm these results and determine whether the increased risk is restricted to *MLH1* mutation carriers. At present, female carriers of an MMR gene mutation should be advised to participate in population screening programmes for breast cancer (biannual mammography from the age of 45 or 50 years).

General conclusion

A recent analysis on the causes of deaths in LS revealed that a large proportion (61%) of the cancer deaths were now associated with non-CRC non-EC.⁸⁵ Unfortunately, the benefit of surveillance for most extracolonic cancers is still unknown. Surveillance for these cancers should therefore only be performed in a research setting. The results of long-term surveillance should ideally be collected and evaluated at a regional or national or international LS registry.

To ensure informed decision-making about surveillance by patients, all pros and cons of such programmes should be discussed with the patient. If surveillance is offered, patients should understand that there is uncertainty about the potential benefits and harms. Table 7 shows the protocol recommended by the Mallorca group.

QUESTION NO 6

What is the appropriate surgical treatment for CRC?

Relevant literature

In LS, the risk of developing a second CRC after partial colectomy for primary CRC has been reported to be approximately 16% at 10 years follow-up despite close surveillance.^{86 87} In view of this risk, more extensive treatment (total or subtotal colectomy) of the primary CRC might be considered. However, for decision-making it is important to address the following questions to determine the benefit of the patient: what is the risk of developing a second cancer under appropriate (post-operative) surveillance; and what is the effect of more extensive surgery on the functional outcome and quality of life.

Table 7 Surveillance protocol in LS

Site of cancer	Lower age limit (years)	Examination	Interval (years)
Colorectum	20–25	Colonoscopy	1–2
Uterus/ ovaries	35–40	Offer gynaecological examination, transvaginal ultrasound, aspiration biopsy, discuss pros and cons	1–2
Stomach	30–35	Upper gastrointestinal endoscopy only recommended in LS families from countries with high incidence of gastric cancer, preferably in research setting; Screening of all carriers >25 years for <i>H pylori</i> infection	1–2
Urinary tract	30–35	Surveillance (by urine cytology and ultrasound) of <i>MSH2</i> carriers only in research setting or if results are systematically collected by LS registry	1

LS, Lynch syndrome.

Three recent studies reported the risk of developing an interval CRC under colonoscopic surveillance.^{44–46} In one study, a risk of 6% after 10 years of follow-up was reported.⁴⁵ In the other studies, the risk of developing CRC by the age of 60 years was between 22% and 35% depending on sex and surveillance interval.^{44–46} One study especially evaluated the functional outcome and quality of life after limited and extensive surgery in LS patients.⁸⁸ Although the functional outcome was significantly worse after extensive surgery, quality of life was similar in both groups.

Conclusion

In view of the substantial risk of a second CRC after partial colectomy (category of evidence III) and similar quality of life after partial and subtotal colectomy (category of evidence III), the option of subtotal colectomy including its pros and cons⁸⁹ should be discussed with all LS patients with CRC, especially younger patients (grade of recommendation C).

QUESTION NO 7

What is the influence of environmental and lifestyle factors on the development of adenoma or CRC in LS?

Relevant literature

There is ample evidence that the risk of developing cancer in LS is influenced by environmental factors. The tumour spectrum observed in the first LS syndrome family published in 1913 by

Warthin⁴ included mainly gastric cancers and EC. Follow-up reports of this well-known family showed that in the current generations CRC was now the most common tumour.⁹⁰ The changes reflect the decrease of gastric cancer and increase of CRC in the general population in western countries.

In addition, the spectrum of cancers in LS reported in Japan and South Korea also differs from the spectrum found in LS families in western countries, with more gastric cancers reported in families from eastern Asia.⁹¹

An important question is which environmental and lifestyle factors influence the development of cancer in LS. In the past decade a large number of studies have been published that addressed this question. The studies are summarised in table 8.^{92–99}

Four studies showed that smoking was associated with a higher risk of developing colorectal neoplasias. In addition, two studies demonstrated that a higher body mass index (BMI) was associated with an increased risk of colorectal neoplasia. Alcohol (two out of three studies) was not associated and fruit and fibre intake was possibly related to decreased risks. A recent large randomised controlled trial showed that resistant starch (a component of dietary fibre) had no effect on the development of CRC in LS.¹⁰⁰ Another study investigated the effect of various dietary patterns on the development of adenomas in LS.⁹⁹ A 'snack' dietary pattern was associated with a higher risk of adenoma development.

Conclusion

Smoking and a high BMI increase the risk of developing adenomas and CRC in LS (category of evidence IIb). Patients are advised to stay within the normal weight range and refrain from smoking (grade of recommendation B).

QUESTION NO 8

What is the role of aspirin in the management of LS?

Relevant literature

The CAPP2 trial randomly assigned 1009 LS carriers to two tablets (600 mg) of enteric-coated aspirin daily for 2–4 years. The overall burden of adenomas and carcinomas at the end of the intervention phase was unchanged,¹⁰¹ but re-analysis when the first recruits reached the planned long-term follow-up target of 10 years revealed a significant reduction in CRC and other cancers among those randomly assigned to aspirin versus

Table 8 Outcome of studies on the effect of environmental factors on the risk of adenomas and CRC in LS

Author/year	Type of study	No of participants	Environmental factor	Endpoint	Outcome
Voskuil <i>et al</i> (2002) ⁹²	Case-control	62 Cases 83 Controls	Meat	Adenomas	No association
Diergaarde <i>et al</i> (2007) ⁹³	Case-control	145 Cases 103 Controls	Alcohol/smoking Fruit/fibre	Adenomas Adenomas	Increased risk Decreased risk
Watson <i>et al</i> (2004) ⁹⁴	Retrospective analysis	360 Carriers 271 Carriers	Smoking Alcohol	CRC CRC	Increased risk No association
Pande <i>et al</i> (2010) ⁹⁵	Retrospective analysis	752 Carriers	Smoking	CRC	Increased risk
Botma <i>et al</i> (2010) ⁹⁶	Prospective cohort study	468 Carriers	BMI	Adenomas	Increased risk in males
Win <i>et al</i> (2011) ⁹⁷	Retrospective analysis	1324 Carriers 1219 Non-carriers	BMI	CRC	Increased risk
Winkels <i>et al</i> (2012) ⁹⁸	Prospective cohort study	468 Carriers	Smoking Alcohol	Adenomas Adenomas	Increased risk No significant association
Mathers <i>et al</i> (2012) ¹⁰⁰	Randomised controlled trial	918 Carriers	Resistant starch	CRC	No effect
Botma <i>et al</i> (2012) ⁹⁹	Prospective cohort study	468 Carriers	Dietary patterns	Adenomas	With 'snack' dietary pattern* increased risk of adenomas

*'Snack' dietary pattern: high intake of chips, fried snacks, fast food snacks, spring rolls, mayonnaise based sauces, cooking fat and butter, peanut sauce, ketchup, sweets and soda water. BMI, body mass index; CRC, colorectal cancer; LS, Lynch syndrome.

Guidelines

those randomly assigned to placebo. The study remained double blind.¹⁰² Forty-eight participants developed 53 primary CRC (18 recruits with 19 CRC/427 randomly assigned to aspirin, 30 recruits with 34 CRC/434 assigned to aspirin placebo). Intention-to-treat analysis of the time to first CRC showed a HR of 0.63 (95% CI 0.35 to 1.13, $p=0.12$). Poisson regression taking account of the multiple primary events gave an incidence rate ratio (IRR) of 0.56 (95% CI 0.32 to 0.99, $p=0.05$). The primary endpoint of the trial was the number, size and stage of CRC after 2 years aspirin treatment. This 'per protocol' analysis yielded a HR of 0.41 (95% CI 0.19 to 0.86, $p=0.02$) and an IRR of 0.37 (95% CI 0.18 to 0.78, $p=0.008$). Secondary analysis revealed fewer LS-related cancers in those on aspirin for at least 2 years (IRR 0.42, 95% CI 0.25 to 0.72, $p=0.001$). There was a negative association of LS cancer incidence with the numbers of aspirin taken ($p=0.002$). In other words, the more aspirin someone had taken, the greater was the reduction in cancers developed in the gastrointestinal tract and elsewhere.

A meta-analysis conducted by Rothwell *et al*¹⁰³ included a total of eight randomised trials on the prevention of vascular disease (seven placebo controlled) that examined daily aspirin use with an initial aspirin treatment period of at least 4 years). Using cancer registry data the impact on subsequent cancer incidence and mortality was investigated. Among the eight trials, with a total of 25 570 patients and 674 cancer-related deaths, aspirin treatment using doses between 75 and 1200 mg per day was associated with a 21% lower risk of death from any cancer during the in-trial follow-up period. Among those with data on cancer site, patients randomly assigned to aspirin had a reduced risk of CRC mortality that approached statistical significance (HR 0.41; 95% CI 0.17 to 1.00), an effect that became apparent 5 years after the initiation of aspirin treatment. The review suggested there was no greater benefit with doses higher than 75 mg per day, although adverse effects in the gut increased with higher doses. A dose inferiority trial, CaPP3, will start in 2013. Combining the available data, the recommendation is that all LS gene carriers should consider regular daily aspirin starting with their regular surveillance and that, when available, they should consider helping with studies to determine the optimal dose.

The importance of testing for *H pylori* and subsequent eradication if detected has already been discussed in the section on surveillance for gastric cancer (see question 5). Before starting aspirin, eradication of *H pylori* may also be beneficial because it may decrease the risk of upper gastrointestinal tract injury, especially in those carriers with a history of peptic ulcer or complications.¹⁰⁴

Conclusion

Regular aspirin significantly reduces the incidence of cancer in LS (category of evidence Ib).

The optimal dose will be determined by further randomised studies. Given the lack of additional benefit revealed in the meta-analyses of follow-up data from former 'vascular' trials, a reasonable inference is that the option of taking low-dose aspirin should be discussed with gene carriers, including the risks, benefits and current limitations of available evidence (category of evidence IIb).

QUESTION NO 9

What is the role of prenatal diagnosis (PND) and preimplantation genetic diagnosis (PGD) in LS?

Relevant literature

For some individuals, learning that they have LS may have implications for reproductive decision-making. In some cases, this knowledge impacts on the timing of decisions about having children—for example, because of their desire to have children before pursuing prophylactic salpingo-oophorectomy. In addition, some men and women planning on having children in the future may have concerns about possibly passing the genetic risk of LS-related cancers to their children.

Individuals with LS should be adequately counselled about the risk of transmitting their hereditary predisposition to their future children and regarding their options for PND and PGD, including a complete discussion about the legal, practical and psychological aspects of these decisions and also the availability in various countries.¹⁰⁵

PND is a technique that is performed in early pregnancy. If the family mutation is detected, abortion can be offered. PGD is a technique that always takes place in conjunction with assisted reproduction (in-vitro fertilisation; IVF). Following a successful IVF procedure, one to two cells from the blastocyst can be tested for the family mutation. Only those embryos without the relevant mutation are selected for placement in the uterus.

Dewanwala *et al*¹⁰⁶ recently reported that of patients found to carry a gene mutation associated with LS, 42% would consider using prenatal testing and one in five women would consider having children earlier in order to proceed with prophylactic surgery to reduce their risk of developing gynaecological cancers. In addition, the majority of individuals undergoing genetic testing for LS felt that it would be ethical to offer prenatal genetic testing, either PND or PGD, to those with pathogenic MMR gene mutations. Interestingly, while most of the subjects in their study believed prenatal testing would be ethical, only a minority would consider it themselves. These facts reinforce the idea that decisions regarding childbearing are very personal ones and may be influenced by an individual's personal and family history of cancer.

Conclusion and recommendation

Cancer geneticists and genetic counsellors should be prepared to discuss the option of PND and assisted reproductive technologies during genetic counselling of individuals with LS who are of childbearing age (grade of recommendation C).

QUESTION NO 10

What are the psychosocial implications of genetic testing and surveillance?

Relevant literature

Many studies have evaluated the psychological distress of genetic testing for LS. Most studies showed that immediately after disclosure of the test result, distress significantly increases, but decreases again after 6 months.^{107–115} Long-term studies have demonstrated that post-result increases in distress return to baseline by 1–3 years.^{114–116} However, a substantial subgroup may experience adjustment problems.^{107–115}

The psychological implications of surveillance for hereditary cancer has recently been reviewed by Gopie *et al*.¹¹⁷ In general, normal psychosocial functioning was reported in LS families, and a percentage comparable to the normal general population (10%) had clinically relevant distress levels. However, individuals with a higher cancer risk perception, decreased vitality,

lower general mental health status and more anxiety are at risk of developing psychological problems.^{118–120}

In a Swedish study on 240 individuals at high risk of CRC (including MMR gene mutation carriers, HNPCC family members and individuals with familial CRC) evaluation of the quality of life using SF-36 (five of eight scales) showed generally normal levels but lower levels regarding mental health and vitality compared with the reference population.¹¹⁹ A study from the Danish HNPCC register demonstrated that living with the knowledge of LS has limited impact on self-concept.¹²¹

Three studies evaluated the experience of patients undergoing colonoscopies. The studies showed that a substantial proportion of these patients (30–60%) considered undergoing colonoscopies as unpleasant, painful and frightening.^{59 118 122}

After being counselled about genetic test results, index patients play an important role in the communication of information regarding LS, the gene defect in the family and the preventive measures. Aktan-Collan *et al*¹²³ investigated how parents with LS share knowledge of genetic risk with their offspring. The study reported that out of 248 mutation carriers with children, 87% reported disclosure and 13% non-disclosure. Reasons for non-disclosure were mainly the young age of offspring, socially distant relationships, or a feeling of difficulty in discussing the topic. The most difficult communication aspect was discussing cancer risk with offspring. One third of the parents suggested that health professionals should be involved in passing on this information and that a family appointment at the genetic clinic should be organised at the time of disclosure. The authors concluded that it is a great challenge to improve the communication processes, so that all offspring get information that is important for their healthcare and parents get the professional support they desire at the time of disclosure to their children.

Recommendation

Professionals should be aware of the potential psychosocial problems before and after genetic testing and during follow-up and surveillance visits. People with increased psychological distress should be offered referral to a clinical psychologist. All efforts should be made to make colonoscopies as comfortable as possible by paying full attention to adequate pain control and sedation.

Author affiliations

¹Department of Gastroenterology, Leiden University Medical Centre, Leiden, The Netherlands

²Hereditary Cancer Program, Catalan Institute of Oncology, Barcelona, Spain

³Department of Medical Genetics Haartman Institute Biomedicum, University of Helsinki, Helsinki, Finland

⁴Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands

⁵Department of Medical Genetics, Complejo Hospitalario de Navarra, Pamplona, Spain

⁶Institute of Human Genetics, University Hospital, Bonn, Germany

⁷The Danish HNPCC-Register, Department of Gastroenterology and Clinical Research Center, Copenhagen University Hospital, Hvidovre, Denmark

⁸Department of Surgery, Hospital Tumori, Milan, Italy

⁹Institute of Human Genetics, Newcastle upon Tyne, UK

¹⁰Department of Genetics, Hospital Pitié-Salpêtrière APHP, Paris, France

¹¹Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany

¹²Institute of Medical Genetics, Cardiff University and University Hospital of Wales, Cardiff, UK

¹³Department of Clinical Pathophysiology, University of Florence, and Tuscan Tumor Institute, Florence, Italy

¹⁴Division of Medical Genetics and Department of Biomedicine, University of Children's Hospital, Basel, Switzerland

¹⁵Department of Clinical Genetics, St George's University of London Hospital, London, UK

¹⁶Department of Gastroenterology, Konstantopoulo University Hospital, Athens, Greece

¹⁷Genetic Medicine, Central Manchester University Hospitals NHS Foundation Trust,

Manchester Academic Health Scientist Centre, Manchester, UK

¹⁸Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

¹⁹Department of Surgery, Jyväskylä Central Hospital, Jyväskylä & Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland

²⁰Department of Medical Genetics, The Norwegian Radium Hospital University Hospital, Oslo, Norway

²¹Department of Gastroenterology, University Medical Centre Radboud, Nijmegen, The Netherlands

²²Department of Digestive Surgery, Hospital Saint-Antoine, University Pierre et Marie, Paris, France

²³Department of Internal Medicine, Universtiy Hospital, Modena, Italy

²⁴Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland

²⁵Department of Genetics, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

²⁶Digestive Oncology Unit, Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium.

²⁷Family Cancer Clinics, St Mark's Hospital, CRUK Cancer Centre, Imperial College London, Harrow, UK

²⁸Medical Faculty, Institute of Human Genetics, University of Duesseldorf, Duesseldorf, Germany

²⁹Department of Surgery, HELIOS St Josefs Hospital Bochum-Linden (Helios), Bochum, Germany

Contributors The guidelines have been discussed during two workshops.

All authors were involved in this discussion. The manuscript was written by HFAV with specific contributions from IB (question 9) and from KAC and JPG (question 10).

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

1. Lynch HT, Lynch PM, Lanspa SJ, *et al*. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. *Clin Genet* 2009;**76**:1–18.
2. Vasen HF, Moslein G, Alonso A, *et al*. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. *Fam Cancer* 2010;**9**:109–15.
3. Vasen HF, Moslein G, Alonso A, *et al*. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). *J Med Genet* 2007;**44**:353–62.
4. Warthin A.S. Heredity with reference to carcinoma. *Arch Int Med* 1913;**12**:546–55.
5. Lynch HT, Shaw MW, Magnuson CW, *et al*. Hereditary factors in cancer. Study of two large midwestern kindreds. *Arch Intern Med* 1966;**117**:206–12.
6. Ligtenberg MJ, Kuiper RP, Chan TL, *et al*. Heritable somatic methylation and inactivation of *MSH2* in families with Lynch syndrome due to deletion of the 3' exons of *TACSTD1*. *Nat Genet* 2009;**41**:112–17.
7. Kovacs ME, Papp J, Szentirmay Z, *et al*. Deletions removing the last exon of *TACSTD1* constitute a distinct class of mutations predisposing to Lynch syndrome. *Hum Mutat* 2009;**30**:197–203.
8. Aarnio M, Sankila R, Pukkala E, *et al*. Cancer risk in mutation carriers of DNA-mismatch-repair genes. *Int J Cancer* 1999;**81**:214–18.
9. Vasen HF, Stormorken A, Menko FH, *et al*. *MSH2* mutation carriers are at higher risk of cancer than *MLH1* mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. *J Clin Oncol* 2001;**19**:4074–80.
10. Hampel H, Stephens JA, Pukkala E, *et al*. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. *Gastroenterology* 2005;**129**:415–21.
11. Barrow E, Robinson L, Alduaij W, *et al*. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. *Clin Genet* 2009;**75**:141–9.
12. Watson P, Vasen HF, Mecklin JP, *et al*. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer* 2008;**123**:444–9.
13. Bonadona V, Bonaïti B, Olschwang S, *et al*. Cancer risks associated with germline mutations in *MLH1*, *MSH2*, and *MSH6* genes in Lynch syndrome. *JAMA* 2011;**305**:2304–10.
14. Baglietto L, Lindor NM, Dowty JG, *et al*. Risks of Lynch syndrome cancers for *MSH6* mutation carriers. *J Natl Cancer Inst* 2010;**102**:193–201.
15. ten Kate GL, Kleibeuker JH, Nagengast FM, *et al*. Is surveillance of the small bowel indicated for Lynch syndrome families? *Gut* 2007;**56**:1198–201.
16. Grindel EM, Moller P, Eeles R, *et al*. Germ-line mutations in mismatch repair genes associated with prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2009;**18**:2460–7.

Guidelines

17. **Capelle LG**, Van Grieken NC, Lingsma HF, *et al*. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. *Gastroenterology* 2010;**138**:487–92.
18. **van der Post RS**, Kiemeny LA, Ligtenberg MJ, *et al*. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among *MSH2* mutation carriers. *J Med Genet* 2010;**47**:464–70.
19. **Engel C**, Loeffler M, Steinke V, *et al*. Risks of less common cancers in proven mutation carriers with Lynch syndrome. *J Clin Oncol* 2012;**30**:4409–15.
20. **Kastrinos F**, Mukherjee B, Tayob N, *et al*. Risk of pancreatic cancer in families with Lynch syndrome. *JAMA* 2009;**302**:1790–5.
21. **Barrow PJ**, Ingham S, O'Hara C, *et al*. The spectrum of urological malignancy in Lynch syndrome. *Fam Cancer* 2013;**12**:57–63.
22. **Kempers MJ**, Kuiper RP, Ockeloen CW, *et al*. Risk of colorectal and endometrial cancers in *EPCAM* deletion-positive Lynch syndrome: a cohort study. *Lancet Oncol* 2011;**12**:49–55.
23. **Dunlop MG**, Tenesa A, Farrington SM, *et al*. Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42 103 individuals. *Gut* 2013;**62**:871–81.
24. **Wijnen JT**, Brohet RM, van Eijk R, *et al*. Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. *Gastroenterology* 2009;**136**:131–7.
25. **Talseth-Palmer BA**, Scott RJ, Vasen HF, *et al*. 8q23.3 and 11q23.1 as modifying loci influencing the risk for CRC in Lynch syndrome. *Eur J Hum Genet* 2012;**20**:487–8.
26. **Houille S**, Charbonnier F, Houivet E, *et al*. Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. *Eur J Hum Genet* 2011;**19**:887–92.
27. **Jarvinen HJ**, Aarnio M, Mustonen H, *et al*. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. *Gastroenterology* 2000;**118**:829–34.
28. **Trano G**, Wasmuth HH, Sjursen W, *et al*. Awareness of heredity in colorectal cancer patients is insufficient among clinicians: a Norwegian population-based study. *Colorectal Dis* 2009;**11**:456–61.
29. **Umar A**, Boland CR, Terdiman JP, *et al*. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;**96**:261–8.
30. **Hampel H**, Frankel WL, Martin E, *et al*. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med* 2005;**352**:1851–60.
31. **Hampel H**, Frankel WL, Martin E, *et al*. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. *J Clin Oncol* 2008;**26**:5783–8.
32. **Julie C**, Tresallet C, Brouquet A, *et al*. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. *Am J Gastroenterol* 2008;**103**:2825–35.
33. **van Lier MG**, Leenen CH, Wagner A, *et al*. Yield of routine molecular analyses in colorectal cancer patients ≤ 70 years to detect underlying Lynch syndrome. *J Pathol* 2012;**226**:764–74.
34. **Perez-Carbonell L**, Ruiz-Ponte C, Guarinos C, *et al*. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. *Gut* 2012;**61**:865–72.
35. **Canard G**, Lefevre JH, Colas C, *et al*. Screening for Lynch syndrome in colorectal cancer: are we doing enough? *Ann Surg Oncol* 2012;**19**:809–16.
36. **Moreira L**, Balaguer F, Lindor N, *et al*. Identification of Lynch syndrome among patients with colorectal cancer. *JAMA* 2012;**308**:1555–65.
37. **Mvundura M**, Grosse SD, Hampel H, *et al*. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. *Genet Med* 2010;**12**:93–104.
38. **Ladabaum U**, Wang G, Terdiman J, *et al*. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. *Ann Intern Med* 2011;**155**:69–79.
39. **Hampel H**, Frankel W, Panescu J, *et al*. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. *Cancer Res* 2006;**66**:7810–17.
40. **Leenen CH**, van Lier MG, van Doorn HC, *et al*. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. *Gynecol Oncol* 2012;**125**:414–20.
41. **Resnick K**, Straughn JM Jr, Backes F, *et al*. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. *Obstet Gynecol* 2009;**114**:530–6.
42. **Plocharczyk EF**, Frankel WL, Hampel H, *et al*. Mismatch repair protein deficiency is common in sebaceous neoplasms and suggests the importance of screening for Lynch syndrome. *Am J Dermatopathol* Published Online First: 20 June 2012. doi: 10.1097/DAD.0b013e31825f7efe
43. **Jarvinen HJ**, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. *Gastroenterology* 1995;**108**:1405–11.
44. **Mecklin JP**, Aarnio M, Laara E, *et al*. Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. *Gastroenterology* 2007;**133**:1093–8.
45. **Vasen HF**, Abdurahman M, Brohet R, *et al*. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. *Gastroenterology* 2010;**138**:2300–6.
46. **Engel C**, Rahner N, Schulmann K, *et al*. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. *Clin Gastroenterol Hepatol* 2010;**8**:174–82.
47. **Stuckless S**, Green J, Morgenstern M, *et al*. Impact of colonoscopic screening in male and female Lynch syndrome carriers with an *MSH2* mutation. *Clin Genet* 2012;**82**:439–45.
48. **de Jong AE**, Hendriks YM, Kleibeuker JH, *et al*. Decrease in mortality in Lynch syndrome families because of surveillance. *Gastroenterology* 2006;**130**:665–71.
49. **Quehenberger F**, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the *hMLH1* and *hMSH2* gene: correction for ascertainment. *J Med Genet* 2005;**42**:491–6.
50. **Nieminen TT**, Gylling A, Abdel-Rahman WM, *et al*. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. *Clin Cancer Res* 2009;**15**:5772–83.
51. **Auranen A**, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. *Acta Obstet Gynecol Scand* 2011;**90**:437–44.
52. **Dove-Edwin I**, Boks D, Goff S, *et al*. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. *Cancer* 2002;**94**:1708–12.
53. **Rijcken FE**, Mourits MJ, Kleibeuker JH, *et al*. Gynecologic screening in hereditary nonpolyposis colorectal cancer. *Gynecol Oncol* 2003;**91**:74–80.
54. **Renkonen-Sinisalo L**, Butzow R, Leminen A, *et al*. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. *Int J Cancer* 2007;**120**:821–4.
55. **Lecuru F**, Le Frere Belda MA, Bats AS, *et al*. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. *Int J Gynecol Cancer* 2008;**18**:1326–31.
56. **Gerritzen LH**, Hoogerbrugge N, Oei AL, *et al*. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. *Fam Cancer* 2009;**8**:391–7.
57. **Stuckless S**, Green J, Dawson L, *et al*. Impact of gynecological screening in Lynch syndrome carriers with an *MSH2* mutation. *Clin Genet* Published Online First: 7 August 2012. doi: 10.1111/j.1399-0004.2012.01929.x
58. **Elmasry K**, Davies AJ, Evans DG, *et al*. Strategies for endometrial screening in the Lynch syndrome population: a patient acceptability study. *Fam Cancer* 2009;**8**:431–9.
59. **Huang M**, Sun C, Boyd-Rogers S, *et al*. Prospective study of combined colon and endometrial cancer screening in women with Lynch syndrome: a patient-centered approach. *J Oncol Pract* 2011;**7**:43–7.
60. **Wood NJ**, Munot S, Sheridan E, *et al*. Does a 'one-stop' gynecology screening clinic for women in hereditary nonpolyposis colorectal cancer families have an impact on their psychological morbidity and perception of health? *Int J Gynecol Cancer* 2008;**18**:279–84.
61. **Schmeler KM**, Lynch HT, Chen LM, *et al*. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med* 2006;**354**:261–9.
62. **Schmeler KM**, Daniels MS, Soliman PT, *et al*. Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. *Obstet Gynecol* 2010;**115**:432–4.
63. **Yang KY**, Caughey AB, Little SE, *et al*. A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) families. *Fam Cancer* 2011;**10**:535–43.
64. **Kwon JS**, Sun CC, Peterson SK, *et al*. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. *Cancer* 2008;**113**:326–35.
65. **Crijnen TE**, Janssen-Heijnen ML, Gelderblom H, *et al*. Survival of patients with ovarian cancer due to a mismatch repair defect. *Fam Cancer* 2005;**4**:301–5.
66. **Grindedal EM**, Renkonen-Sinisalo L, Vasen H, *et al*. Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. *J Med Genet* 2010;**47**:99–102.
67. **Ketabi Z**, Bartuma K, Bernstein I, *et al*. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. *Gynecol Oncol* 2011;**121**:462–5.
68. **Madalinska JB**, Hollenstein J, Bleiker E, *et al*. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. *J Clin Oncol* 2005;**23**:6890–8.
69. **Madalinska JB**, van BM, Bleiker EM, *et al*. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. *J Clin Oncol* 2006;**24**:3576–82.
70. **Watson P**, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. *Cancer* 1993;**71**:677–85.
71. **Lauwers GY**, Carneiro F, Graham DY, *et al*. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. *WHO classification of tumours of the digestive system*, 2012, IARC, Lyon, 2010.

72. **Aarnio M**, Salovaara R, Aaltonen LA, *et al*. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. *Int J Cancer* 1997;**74**:551–5.
73. **Renkonen-Sinisalo L**, Sipponen P, Aarnio M, *et al*. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. *Scand J Gastroenterol* 2002;**37**:574–7.
74. **Saurin JC**, Pilleul F, Soussan EB, *et al*. Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndrome. *Endoscopy* 2010;**42**:1057–62.
75. **Win AK**, Young JP, Lindor NM, *et al*. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol* 2012;**30**:958–64.
76. **Hemstreet GP III**, Yin S, Ma Z, *et al*. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. *J Natl Cancer Inst* 2001;**93**:427–36.
77. **Marsh GM**, Callahan C, Pavlock D, *et al*. A protocol for bladder cancer screening and medical surveillance among high-risk groups: the Drake Health Registry experience. *J Occup Med* 1990;**32**:881–6.
78. **Marsh GM**, Cassidy LD. The Drake Health Registry Study: findings from fifteen years of continuous bladder cancer screening. *Am J Ind Med* 2003;**43**:142–8.
79. **Theriault GP**, Tremblay CG, Armstrong BG. Bladder cancer screening among primary aluminum production workers in Quebec. *J Occup Med* 1990;**32**:869–72.
80. **Myrhoj T**, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. *Fam Cancer* 2008;**7**:303–7.
81. **Scott RJ**, McPhillips M, Meldrum CJ, *et al*. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. *Am J Hum Genet* 2001;**68**:118–27.
82. **Vasen HF**, Morreau H, Nortier JW. Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer? *Am J Hum Genet* 2001;**68**:1533–5.
83. **Jensen UB**, Sunde L, Timshel S, *et al*. Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. *Breast Cancer Res Treat* 2010;**120**:777–82.
84. **Buerki N**, Gautier L, Kovac M, *et al*. Evidence for breast cancer as an integral part of Lynch syndrome. *Genes Chromosomes Cancer* 2012;**51**:83–91.
85. **Pylvanainen K**, Lehtinen T, Kellokumpu I, *et al*. Causes of death of mutation carriers in Finnish Lynch syndrome families. *Fam Cancer* 2012;**11**:467–71.
86. **de Vos tot Nederveen Cappel WH**, Nagengast FM, Griffioen G, *et al*. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. *Dis Colon Rectum* 2002;**45**:1588–94.
87. **Parry S**, Win AK, Parry B, *et al*. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. *Gut* 2010;**60**:950–7.
88. **Haanstra JF**, de Vos tot Nederveen Cappel WH, Gopie JP, *et al*. Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy. *Dis Colon Rectum* 2012;**55**:653–9.
89. **Vasen HF**, de Vos tot Nederveen Cappel WH. Cancer: Lynch syndrome—how should colorectal cancer be managed? *Nat Rev Gastroenterol Hepatol* 2011;**8**:184–6.
90. **Lynch HT**, Krush AJ. Cancer family 'G' revisited: 1895–1970. *Cancer* 1971;**27**:1505–11.
91. **Park JG**, Park YJ, Wijnen JT, *et al*. Gene–environment interaction in hereditary nonpolyposis colorectal cancer with implications for diagnosis and genetic testing. *Int J Cancer* 1999;**82**:516–19.
92. **Voskuil DW**, Kampman E, Grubben MJ, *et al*. Meat consumption and meat preparation in relation to colorectal adenomas among sporadic and HNPCC family patients in The Netherlands. *Eur J Cancer* 2002;**38**:2300–8.
93. **Diergaarde B**, Braam H, Vasen HF, *et al*. Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. *Clin Gastroenterol Hepatol* 2007;**5**:736–42.
94. **Watson P**, Ashwathnarayan R, Lynch HT, *et al*. Tobacco use and increased colorectal cancer risk in patients with hereditary nonpolyposis colorectal cancer (Lynch syndrome). *Arch Intern Med* 2004;**164**:2429–31.
95. **Pande M**, Lynch PM, Hopper JL, *et al*. Smoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. *Clin Cancer Res* 2010;**16**:1331–9.
96. **Botma A**, Nagengast FM, Braem MG, *et al*. Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOlynch cohort study. *J Clin Oncol* 2010;**28**:4346–53.
97. **Win AK**, Dowty JG, English DR, *et al*. Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes. *Br J Cancer* 2011;**105**:162–9.
98. **Winkels RM**, Botma A, Van Duijnhoven FJ, *et al*. Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. *Gastroenterology* 2012;**142**:241–7.
99. **Botma A**, Vasen HF, Van Duijnhoven FJ, *et al*. Dietary patterns and colorectal adenomas in Lynch syndrome: the GEOlynch Cohort Study. *Cancer* 2013; 119:512–21.
100. **Mathers JC**, Movahedi M, Macrae F, *et al*. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet Oncol* 2012;**13**:1242–9.
101. **Burn J**, Bishop DT, Mecklin JP, *et al*. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. *N Engl J Med* 2008;**359**:2567–78.
102. **Burn J**, Gerdes AM, Macrae F, *et al*. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet* 2011;**378**:2081–7.
103. **Rothwell PM**, Fowkes FG, Belch JF, *et al*. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* 2011;**377**:31–41.
104. **Leung Ki EL**, Chan FK. Interaction of *Helicobacter pylori* infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice. *Best Pract Res Clin Gastroenterol* 2012;**26**:163–72.
105. **Clancy T**. A clinical perspective on ethical arguments around prenatal diagnosis and preimplantation genetic diagnosis for later onset inherited cancer predispositions. *Fam Cancer* 2010;**9**:9–14.
106. **Dewanwala A**, Chittenden A, Rosenblatt M, *et al*. Attitudes toward childbearing and prenatal testing in individuals undergoing genetic testing for Lynch syndrome. *Fam Cancer* 2011;**10**:549–56.
107. **Esplen MJ**, Madlensky L, Butler K, *et al*. Motivations and psychosocial impact of genetic testing for HNPCC. *Am J Med Genet* 2001;**103**:9–15.
108. **Lerman C**, Hughes C, Trock BJ, *et al*. Genetic testing in families with hereditary nonpolyposis colon cancer. *JAMA* 1999;**281**:1618–22.
109. **Aktan-Collan K**, Haukka A, Mecklin JP, *et al*. Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study. *Int J Cancer* 2001;**93**:608–11.
110. **Claes E**, Evers-Kiebooms G, Denayer L, *et al*. Predictive genetic testing for hereditary breast and ovarian cancer: psychological distress and illness representations 1 year following disclosure. *J Genet Couns* 2005;**14**:349–63.
111. **Murakami Y**, Okamura H, Sugano K, *et al*. Psychologic distress after disclosure of genetic test results regarding hereditary nonpolyposis colorectal carcinoma. *Cancer* 2004;**101**:395–403.
112. **Meiser B**, Collins V, Warren R, *et al*. Psychological impact of genetic testing for hereditary non-polyposis colorectal cancer. *Clin Genet* 2004;**66**:502–11.
113. **Shiloh S**, Koehly L, Jenkins J, *et al*. Monitoring coping style moderates emotional reactions to genetic testing for hereditary nonpolyposis colorectal cancer: a longitudinal study. *Psychooncology* 2008;**17**:746–55.
114. **Arver B**, Haegermark A, Platten U, *et al*. Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up. *Fam Cancer* 2004;**3**:109–16.
115. **Heshka JT**, Palleschi C, Howley H, *et al*. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. *Genet Med* 2008;**10**:19–32.
116. **Collins VR**, Meiser B, Ukoumunne OC, *et al*. The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: three years after testing. *Genet Med* 2007;**9**:290–7.
117. **Gopie JP**, Vasen HF, Tibben A. Surveillance for hereditary cancer: does the benefit outweigh the psychological burden? A systematic review. *Crit Rev Oncol Hematol* 2012;**83**:329–40.
118. **Wagner A**, Van Kessel I, Kriege MG, *et al*. Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. *Fam Cancer* 2005;**4**:295–300.
119. **Liljgren A**, Lindgren G, Brandberg Y, *et al*. Individuals with an increased risk of colorectal cancer: perceived benefits and psychological aspects of surveillance by means of regular colonoscopies. *J Clin Oncol* 2004;**22**:1736–42.
120. **Bleiker EM**, Menko FH, Kluij I, *et al*. Colorectal cancer in the family: psychosocial distress and social issues in the years following genetic counselling. *Hered Cancer Clin Pract* 2007;**5**:59–66.
121. **Petersen HV**, Esplen MJ, Ladelund S, *et al*. Limited impact on self-concept in individuals with Lynch syndrome: results from a national cohort study. *Fam Cancer* 2011;**10**:633–9.
122. **Pylvanainen K**, Kairaluoma M, Mecklin JP. Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. *Fam Cancer* 2006;**5**:175–8.
123. **Aktan-Collan KI**, Kaariainen HA, Koltola EM, *et al*. Sharing genetic risk with next generation: mutation-positive parents' communication with their offspring in Lynch syndrome. *Fam Cancer* 2011;**10**:43–50.



Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts

Hans F A Vasen, Ignacio Blanco, Katja Aktan-Collan, Jessica P Gopie, Angel Alonso, Stefan Aretz, Inge Bernstein, Lucio Bertario, John Burn, Gabriel Capella, Chrystelle Colas, Christoph Engel, Ian M Frayling, Maurizio Genuardi, Karl Heinimann, Frederik J Hes, Shirley V Hodgson, John A Karagiannis, Fiona Laloo, Annika Lindblom, Jukka-Pekka Mecklin, Pal Møller, Torben Myrhoj, Fokko M Nagengast, Yann Parc, Maurizio Ponz de Leon, Laura Renkonen-Sinisalo, Julian R Sampson, Astrid Stormorken, Rolf H Sijmons, Sabine Tejpar, Huw J W Thomas, Nils Rahner, Juul T Wijnen, Heikki Juhani Järvinen and Gabriela Möslein

Gut 2013 62: 812-823 originally published online February 13, 2013
doi: 10.1136/gutjnl-2012-304356

Updated information and services can be found at:
<http://gut.bmj.com/content/62/6/812>

These include:

References

This article cites 117 articles, 22 of which you can access for free at:
<http://gut.bmj.com/content/62/6/812#BIBL>

Open Access

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: <http://creativecommons.org/licenses/by-nc/3.0/> and <http://creativecommons.org/licenses/by-nc/3.0/legalcode>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Editor's choice](#) (89)
[Open access](#) (169)
[Colon cancer](#) (1450)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>